Clinical Trial Update: Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of HuMax-CD4 in rheumatoid arthritis patients who failed methotrexate and TNF blockers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• HuMax-CD4

Snippet

Sponsor: Genmab | Conditions: Rheumatoid Arthritis | Phase 2, Phase 3 | Status: TERMINATED